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Abstract
Purpose: To establish the relative weighting given by patients and healthcare professionals to gains in diagnostic sensitivity
versus loss of specificity when using CT colonography (CTC) for colorectal cancer screening.
Materials and Methods: Following ethical approval and informed consent, 75 patients and 50 healthcare professionals
undertook a discrete choice experiment in which they chose between ‘‘standard’’ CTC and ‘‘enhanced’’ CTC that raised
diagnostic sensitivity 10% for either cancer or polyps in exchange for varying levels of specificity. We established the relative
increase in false-positive diagnoses participants traded for an increase in true-positive diagnoses.
Results: Data from 122 participants were analysed. There were 30 (25%) non-traders for the cancer scenario and 20 (16%) for
the polyp scenario. For cancer, the 10% gain in sensitivity was traded up to a median 45% (IQR 25 to .85) drop in
specificity, equating to 2250 (IQR 1250 to .4250) additional false-positives per additional true-positive cancer, at 0.2%
prevalence. For polyps, the figure was 15% (IQR 7.5 to 55), equating to 6 (IQR 3 to 22) additional false-positives per
additional true-positive polyp, at 25% prevalence. Tipping points were significantly higher for patients than professionals for
both cancer (85 vs 25, p,0.001) and polyps (55 vs 15, p,0.001). Patients were willing to pay significantly more for increased
sensitivity for cancer (p = 0.021).
Conclusion: When screening for colorectal cancer, patients and professionals believe gains in true-positive diagnoses are
worth much more than the negative consequences of a corresponding rise in false-positives. Evaluation of screening tests
should account for this.
Citation: Boone D, Mallett S, Zhu S, Yao GL, Bell N, et al. (2013) Patients’ & Healthcare Professionals’ Values Regarding True- & False-Positive Diagnosis when
Colorectal Cancer Screening by CT Colonography: Discrete Choice Experiment. PLoS ONE 8(12): e80767. doi:10.1371/journal.pone.0080767
Editor: Jeroen Hendrikse, University Medical Center (UMC) Utrecht, The Netherlands
Received August 10, 2013; Accepted October 13, 2013; Published December 9, 2013
Copyright:  2013 Boone et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This article presents independent research funded by the UK National Institute for Health Research (NIHR) under its Programme Grants for Applied
Research funding scheme (RP-PG-0407-10338). The views expressed are those of the authors and not necessarily those of the UK NHS, the NIHR, or the
Department of Health. A proportion of this work was undertaken at UCL and UCLH, who receive a proportion of funding from the NIHR Biomedical Research
Centre funding scheme.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: s.halligan@ucl.ac.uk
Introduction
Understanding diagnostic test performance is essential for
evidence-based practice [1,2], particularly for screening where
risks and benefits are balanced finely. No screening test is 100%
sensitive and the consequence is readily understood; false-negative
tests will delay or prevent cure. Specificity is important for
screening because most people are disease-free. A false-positive test
means healthy individuals may undergo invasive procedures
causing anxiety, morbidity, and even mortality [3]. Tests that
increase the proportion of people with disease who test true-
positive (increase sensitivity) usually simultaneously increase the
proportion of people without disease who test false-positive
(diminish specificity). For example, computer-aided-detection
(CAD) [4], digital imaging [5], and shorter screening intervals
[6] all increase mammographic sensitivity for breast cancer but
decrease specificity.
When comparing two diagnostic tests, interpretation is some-
times difficult if one has high sensitivity and the other high
specificity. A combined measure of sensitivity and specificity
facilitates interpretation; examples include net-benefit or the area
under the receiver-operator characteristic curve (ROC AUC) [7–
11]. An advantage of net-benefit measures is that they can
incorporate relative values for gains in true-positive diagnoses
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versus costs of false-negative diagnoses, whereas ROC AUC
cannot. However, few studies have quantified these costs and those
that have suggest they are valued very differently by patients; one
study found women would accept 500 false-positive mammograms
to avoid a single missed cancer [12]. While qualitative research
suggests that attendees value sensitivity over specificity when
screening for colorectal cancer [13,14] this has not been
quantified. Ignoring these preferences may underestimate test
benefit. For example, the Medicaid/Medicare decision to not
reimburse CT colonography (CTC) did not consider that screen-
ees may still value gains in sensitivity despite diminished specificity
[15]. To clarify this issue we established the relative weighting
given by patients and healthcare professionals to additional true-
positive diagnoses compared to additional false-positive diagnoses
(i.e. gains in sensitivity versus loss of specificity) when using CTC
for colorectal cancer screening.
Methods
Ethics Statement
Ethics committee approval was granted by the local institutional
ethical review board of University College Hospitals London; all
participants gave written informed consent.
Design
We designed and conducted a discrete choice experiment
(DCE) [16–18], according to recent guidelines [18]. In particular,
patients may value sensitivity so highly that even small changes can
mask the influence of other attributes [18]. Also, specificity is
conceptually challenging, with patients often unaware that false-
positive diagnoses can occur [13]. Therefore, to simplify decision-
making we used a ‘probability equivalence’ design to establish
attitudes to sensitivity and specificity alone, without the influence
of other attributes. We presented sensitivity and specificity in terms
of differing numbers of true-positive and false-positive diagnoses
by imaging. A hypothetical ‘‘enhanced’’ CTC screening test was
presented against ‘‘standard’’ CTC and participants noted their
preference between the two. Sensitivity and specificity for cancer
for ‘‘standard’’ CTC was 85% and 95% respectively and 80% and
85% for polyps $6 mm. ‘‘Enhanced’’ CTC raised sensitivity for
cancer to 95%, equivalent to detecting one additional cancer per
5000 screenees (cancer prevalence 0.2%) [19,20]. ‘‘Enhanced’’
CTC raised sensitivity for polyps to 90%, equivalent to detecting
125 additional people with polyps per 5000 (polyp prevalence
25%) [21]. We aimed to raise sensitivity by 10% while avoiding a
perfect test, which is unrealistic. Specificity of ‘‘enhanced’’ CTC
was dropped in increments to 10% for cancer and 20% for polyps
(Table 1) across the scenarios. Such extremely low specificity is
unlikely in real practice but necessary to calculate ‘‘tipping points’’,
i.e. the level at which an individual is willing to ‘‘trade’’ one
attribute for the other. In the present case, the tipping point was
the maximum reduction in specificity that participants were
prepared to trade for a 10% absolute (vs relative) increase in
sensitivity.
Because DCEs are difficult to comprehend, especially via postal
questionnaires [22], we used an interviewer-led design for patients,
which clarifies understanding and permits qualitative exploration
afterwards, especially with non-traders [23] (a ‘‘non-trader’’ is a
participant who will not trade their preferred attribute at any cost.
With respect to the present study, this would usually represent an
individual who would accept any value of diminished specificity in
order to achieve 10% increased sensitivity). A multimedia laptop
presentation of colorectal cancer screening by colonoscopy and
CTC was given, including information on survival benefit, that
early detection was not always curative [24], and that that false-
positive CTC caused unnecessary colonoscopy. For clarity, only
the most serious colonoscopic complication was presented,
perforation in 1:500 [25,26]. Because inconsistent framing may
introduce bias [27], both absolute and relative risks were displayed
textually and graphically. Participants were asked to assume they
were average risk for cancer/polyps and that polypectomy would
reduce lifetime disease-specific mortality by 25% [28].
A random scenario was repeated to test consistency. A scenario
with one option unquestionably superior for both sensitivity and
specificity identified ‘‘irrational’’ responders. Finally, we incorpo-
rated ‘‘willingness-to-pay’’ (WTP) assessment: Standard CTC was
pitched against CTC with sensitivity raised by 10% but with
identical specificity. Participants were asked how much, if
anything, they would pay for this.
Pilot
10 volunteers were piloted to confirm comprehensibility and
inform sample size [29]. While understanding attributes and levels,
some did not trade (i.e. they judged the lowest specificity
acceptable). We therefore reprogrammed additional ‘‘stress-slides’’
(automatically triggered by responses accepting the lowest
specificity for enhanced CTC), reinforcing potential harms, to
assess whether heuristic bias anchored their decision. Seemingly
irrational responses declined on repeat piloting of the same
volunteers. Also, participants had been confused by considering
cancer and polyps simultaneously, so the final survey presented
separate cancer and polyp DCEs sequentially, each consisting of
10 scenarios.
Recruitment
We recruited consecutive consenting patients of screening age
(.55 years), scheduled for non-cancer outpatient ultrasound/
plain-radiographic investigations at a teaching hospital, identified
via booking systems. Information/consent forms were mailed and
responders interviewed on their appointment day. To avoid bias
we excluded respondents with a personal history of, or being
investigated for, bowel cancer [30]. All participants were offered a
£10 gift voucher.
To investigate any attitudinal difference between patients and
healthcare professionals, we recruited radiologists, gastroenterol-
ogists, surgeons, nurse-specialists, and radiographers who request-
ed, performed, or interpreted colorectal imaging. To facilitate
recruitment, healthcare professionals could complete the DCE
online since we considered they were familiar with the concepts
presented. Otherwise, a radiologist or clinical psychologist
conducted DCEs, with scenarios presented in random order
within the two DCEs. All participants were asked their age,
ethnicity, education, and household income bracket.
Analysis
Our primary outcome was the reduction in specificity partic-
ipants were willing to ‘‘trade’’ for 10% absolute (vs relative)
increase in sensitivity. We defined the ‘‘tipping-point’’ as the
highest increase in false-positive rate (FPR; 1-specificity) above
baseline at which participants perceived the benefits of increased
sensitivity were outweighed by potential harms. In the pilot this
was 45% for cancer (i.e. participants allowed specificity to fall from
95% to 50% on average). To determine the median tipping point
65% at two-sided alpha 0.05 and 90% power required 96
participants (N = 4s2 zcrit
2/D2 where D= 0.10, p = 0.45,
zcrit = 1.960, s= 0.25) [31]. We pre-specified a secondary outcome
comparing patients and professionals, for which 88 participants
were required for 90% power to detect 15% difference. Because
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our pilot suggested non-normality we recruited a further 15% [31].
The stress-slides were triggered by participants preferring ‘‘en-
hanced’’ CTC despite increasing FPR by 85% for cancer and 65%
for polyps. The highest tipping-point was taken if they traded
subsequently; others were deemed persistent non-traders. Because
participants were presented simultaneously with sensitivity, speci-
ficity, pictorial descriptions of changes and numerical information
on the absolute increase in false-positives compared to increase in
true-positives (Figure 1), we framed our results in terms of false-
positive vs true-positive diagnoses, as this is most easily understood.
The median tipping-point was calculated for cancer and polyps,
for patients/healthcare professionals combined and separately.
Because patient and professional numbers differed we used values
from 1999 bootstrap estimates of median and IQRs, where
samples included equal numbers (n = 50) of each group, therefore
weighting patients and professionals equally. At the tipping point,
the change in specificity equivalent to a 10% change in sensitivity
was converted into a change in the absolute relative numbers of
false-positive and true-positive diagnoses using the equation for net
benefit [11,32]:
net benefit =
sensz 1{prevalenceð Þ=prevalence½ | 1=Wð Þ|
Where D sens = 10%, and Dspec = median tipping point, and W is
the relative weighting (the maximum number of additional false-
positives traded per additional cancer or polyp detected).
Prevalence was assigned 0.2% for cancer, 25% for polyps [19–21].
Tipping points were compared between patients interviewed by
each researcher. Tipping points were highly non-normal so were
summarised by medians and interquartile ranges (IQR 25% to
50%); the median can be interpreted as corresponding to an
average participant. For tipping points and relative weighting of
false-positive to true-positive, all non-traders were treated as
requiring higher FP values than offered (Figure 2: grey values).
The Mann-Whitney U test statistic and Wilcoxon signed rank sum
test were used for unpaired and paired comparison, respectively
(Stata V11.0, Stata Corporation, College Station, Texas).
Results
112 consecutive patients and 62 professionals were invited. 75
patients and 50 healthcare professionals participated, a response of
67% and 81% respectively (Table 2). Three patients could not
complete the DCE leaving 122 for analysis (two medical
professionals gave partial responses). DB interviewed 53, NB
interviewed 48; 21 responses were online. Compared to profes-
sionals, patients were older, discontinued education earlier, and
had lower household income (Table 2).
Non-traders
For cancer detection 30 (25%; 27 patients, 3 professionals)
participants were non-traders, 20 (16%; 18 patients, 2 profession-
Figure 1. Example question from the cancer detection scenario. Each tally mark represents one of 5000 potential outcomes for a patient
undergoing screening: True positive (blue), false negative (yellow), true negative (white), or false positive (red). Participants were informed that if they
were to undertake the test in question, their odds of receiving any of the outcomes were represented by the chance of picking any of these tally-
marks at random ‘‘like roulette’’. Data are also represented numerically using both relative and absolute percentages. This scenario corresponds to
the ‘tipping point’ for patients and professional respondents: On average, participants favoured the enhanced test (test B) in view of its additional
sensitivity up to, but not beyond, this level of additional false positives.
doi:10.1371/journal.pone.0080767.g001
Weighing Sensitivity & Specificity
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D D Spec
als) of who were also non-traders for polyps. Non-traders were
significantly more likely to be patients (27[38%] vs 3[6%]);
p,0.001), were significantly older (median age 64.5 vs 44.5;
p,0.001), and were less educated than traders (15% vs 2% with
no formal qualifications; p,0.001). There was no significant
difference in gender (59% vs 61% female; p = 0.56) or ethnicity
(30% vs 33% non-white; p = 0.57). Considering patients alone,
non-traders (n = 27) were older (median age 66.8 vs 60.1;
p = 0.001), less affluent (median household income GBP10001-
20000 vs. GBP20001-£30000 per annum; p = 0.03. GBP = Great
British Pound, = 1.2 Euros and 1.6 US Dollars at current
exchange rates) and less qualified (median school-leaving age 16
vs. 18yrs; p = 0.02) than traders (n = 45). For cancer and polyps
respectively, 34% (16/47) and 35% (11/31) participants who were
initially unwilling, subsequently traded following the stress-slides.
Cancer
Overall, the median tipping-point for cancer detection occurred
at 45% drop in specificity (IQR 25 to .85%; Table 3). Thus, on
average, a 45% drop in specificity was considered the maximal fall
acceptable in exchange for 10% increased sensitivity. At popula-
tion prevalence of 0.2%, this equates to 2250 (IQR 1250 to
.4250) additional false-positive diagnoses per additional true-
positive cancer. The average number of additional false-positives
per additional true-positive detection was significantly higher for
patients (median 4250 (IQR 2750 to .4250) than professionals
(median 1250, IQR 750 to 2250, p,0.001), i.e. the average
patient perceived a greater number of false-positives acceptable to
gain an additional true-positive.
Polyps
Overall, the median tipping-point for polyp detection was 15%
(IQR 7.5 to 55; Table 3). Thus, on average, a 15% drop in
specificity was considered the maximal fall acceptable in exchange
for 10% increased sensitivity. At population prevalence of 25%,
this equates to 6 (IQR 3 to 22) additional false-positive diagnoses
per additional true-positive polyp. Again, the median number of
additional false-positives per additional true-positive was signifi-
Figure 2. Cumulative graph of participants’ tipping points for trading absolute numbers of true-positive versus false-positive
diagnoses. Each yellow dot shows an individual participant’s trading point. Grey symbols indicate values assigned for participants who refused to
trade. Brown dot shows median value representing ‘‘an average participant’’. Orange dots show 25 and 75 percentage points. Graphs are shown
separately as follows: A; Patients, cancer scenario (n = 72). B; Professionals, cancer scenario (n = 50). C; Patients, polyp scanario (n = 72). D;
Professionals, polyp scanario (n = 50).
doi:10.1371/journal.pone.0080767.g002
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cantly higher for patients (55, IQR 15 to 65) than professionals (15,
IQR 5 to 25. p,0.001).
For patients and professionals combined, the average number of
additional false-positives traded per additional true-positive
detection was significantly higher for cancer than polyps (45 vs
15; p,0.001), indicating that larger falls in specificity were
perceived acceptable when testing for cancer.
There was no significant difference in overall median tipping point
elicited by the radiologist or psychologist, (p = 0.57) nor between
medical professionals’ data obtained face-to-face vs online (p = 0.59).
Table 2. Demographic characteristics and household annual income of patient and professional participants, including non-
traders.
Characteristic Patients (n =72)* Professionals (n=50)** Total (n = 122)
Gender
Female 49 (68) 24 (48) 73 (60)
Male 23 (32) 26 (52) 49 (40)
Age (year)
25–34 0 (0) 26 (52) 26 (21)
35–54 0 (00) 23 (46) 26 (21)
55–59 18 (25) 1 (2) 16 (13)
60–69 40 (56) 0 (0) 40 (33)
70–79 14 (19) 0 (0) 14 (12)
Ethnicity
White 49 (70) 33 (66) 82 (67)
Other 23 (32) 17 (34) 40 (33)
Household income/GBP/year
,10000 3 (4) 0 (0) 3 (3)
10001–20000 14 (19) 0 (0) 14 (11)
20001–30000 19 (26) 3 (6) 22 (18)
30001–40000 10 (14) 9 (18) 19 (15)
.40000 4 (6) 32 (64) 36 (30)
Declined to answer 22 (31) 6 (12) 28 (23)
Data are number (percentage).
*Of the original 75 patients accrued, 3 discontinued the survey without providing any consistent, logical responses. Qualitative exploration by the interviewer revealed
they did not understand the process so data were not included.
**Comprising 5 gastroenterologists, 5 radiologists, 5 colorectal surgeons, 10 Specialist registrars in these specialities, 5 bowel cancer screening nurses and 20 CT
radiographers.
doi:10.1371/journal.pone.0080767.t002
Table 3. Tipping points and relative weighting for cancer and polyp detection scenarios calculated for patients, professionals, and
all participants combined (FP = false-positive diagnosis, TP = true-positive diagnosis).
Tipping point (FP tipping point: max change in
specificity acceptable for a 10% gain in sensitivity)
Relative weighting FP to TP (Average number of additional
FP per additional TP detection)
Median IQR Median IQR
Patients
Polyp 55 15 to 65 22 6 to 26
Cancer 85 55 to .85 4250 2750 to .4250
Professionals
Polyp 15 5 to 25 6 2 to 10
Cancer 25 15 to 45 1250 750 to 2250
Combined
Polyp 15 7.5 to 55 6 3 to 22
Cancer 45 25 to .85 2250 1250 to .4250
doi:10.1371/journal.pone.0080767.t003
Weighing Sensitivity & Specificity
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Willingness-to-pay
Three quarters of participants were willing to give a price range
they would be willing to pay for a test with sensitivity raised by
10% but no loss of specificity. Median WTP was significantly
higher for cancer than polyps: 201–500GBP (IQR 101–200GBP
to 501–1000 GBP) vs. 101–200 GBP (IQR 51–100 to 201–500
GBP), p,0.001, indicating participants felt cancer detection was
worth more than polyp detection. There was no significant
difference in WTP for polyp detection when patients and
professionals were compared (p = 0.97) but patients’ WTP was
significantly higher than professionals’ for cancer detection:
median 201–500 GBP (IQR 101–200 GBP to 201–500GBP) vs
median 101–200 GBP (IQR 51–100 GBP to 201–500 GBP,
p = 0.036). Moreover, median household income was significantly
lower for patients than professionals (20001–25000GBP vs
.40000GBP; p = 0.021, Table 4), indicating that patient’s values
were particularly strongly held from a relative perspective. Most
participants (27 of 32 participants) who declined to answer WTP,
declined to answer for both polyps and cancers. Participants who
declined gave, on average, higher values of false-positives per
additional true-positive diagnosis.
Discussion
In relation to screening for colorectal cancer and polyps,
patients and healthcare professionals both valued gains in
diagnostic sensitivity over and above corresponding loss of
specificity. On average, 2250 additional false-positives were
considered worth trading for a single additional true-positive
diagnosis of cancer and 6 additional false-positives for an
additional true-positive diagnosis of a polyp. Our findings are
similar to those from a study of mammography that found women
willing to trade 500 false-positive mammograms (and their
consequences) in order to diagnose a single additional cancer that
would otherwise have been missed [12]. While it is known that
patients value sensitivity over specificity for colorectal cancer
screening [33,34], we could find no data that quantified this for a
radiological test. Our interest was stimulated by studies of CAD for
CTC, which increases sensitivity but at the cost of reduced
specificity, sometimes significantly [35–38]. However, the poten-
tial clinical consequences of missed cancer (death) are not
equivalent to those of false-positive diagnosis (unnecessary
colonoscopy); our findings confirm that both patients and
healthcare professionals believe this. It is therefore important that
analysis of research studies of diagnostic tests take account of this
asymmetry. Diagnostic tests can be compared using net-benefit
measures, which incorporate relative weightings for different
clinical costs [11,39]. By contrast statistical measures such as ROC
AUC cannot assign different utilities to gains in sensitivity versus
falls in specificity and so could find a new test of no value when
both patients and professionals might think otherwise.
We used a discrete choice experiment, a relatively novel
methodology for establishing preferences [40]. Traditionally,
preferences are elicited via ranking [41], with test attributes
considered in isolation. Results are therefore predictable: Patients
and professionals favour tests that are sensitive, specific, inexpen-
sive, and non-invasive. However, this does not reflect the trade-offs
demanded by real practice. DCEs are increasingly advocated by
researchers because respondents indicate preferences between
different test characteristics, which more accurately reflects real-
world choices [16–18,41–43]. Because DCEs are complex, we
delivered most experiments face-to-face to facilitate understanding
Table 4. Patient and professionals’ willingness to pay (WTP) for a 0.10 (10%) increase in test sensitivity without any reduction in
specificity, for detection of cancer or clinically significant polyps.
WTP/GBP Polyp detection
Patients (72) Professionals (50) Total (122)
n % n % n %
,50 9 12 8 16 17 14
51–100 10 14 8 16 18 15
101–200 15 21 14 28 29 24
201–500 4 6 10 20 14 11
501–1000 10 14 4 8 14 11
.1000 0 0 0 0 0 0
Declined to answer 24 33 6 12 30 25
WTP/GBP Cancer detection
Patients (72) Professionals (50) Total (122)
n % n % n %
,50 5 7 5 10 10 8
51–100 3 4 7 14 10 8
101–200 10 14 12 24 22 18
201–500 14 20 9 18 23 19
501–1000 11 15 6 12 17 14
.1000 8 11 3 6 11 9
Declined to answer 21 29 8 16 29 24
GBP=Great British Pounds.
doi:10.1371/journal.pone.0080767.t004
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and participation, which can increase the generalizability of
results. Accordingly, most participants gave complete, consistent,
meaningful responses. While interviewer bias is possible, we found
no significant difference between responses obtained from the
psychologist or radiologist. Further, there was no significant
difference in responses obtained face-to-face or online.
To simplify and focus the cognitive task, we compared just two
attributes, increase in true-positive and false-positive diagnoses by
imaging (also expressed by sensitivity and specificity). In order to
create an ‘‘enhanced’’ test that inflated sensitivity for cancer to
95% (perfect sensitivity would be unrealistic) we used a baseline
sensitivity of 85% for standard CTC, which is likely an
underestimate. However, in this type of experiment, the relative
weighting given to attributes across different scenarios is key, not
the absolute difference between them. Using this design we elicited
the relative importance that participants placed on gains in
sensitivity versus loss of specificity.
Although both groups valued gains in sensitivity over and above
corresponding loss of specificity, this finding was stronger for
patients. Healthcare professionals, especially those who are
medically qualified, will have a deeper understanding of the pros
and cons of diagnostic testing; as noted earlier, some patients do
not understand that false-positive diagnosis is possible [13].
Patients were older, discontinued education earlier, and had
approximately half the annual household income of health
professionals, yet patients ascribed a monetary value to enhanced
sensitivity that was approximately twice that of professionals,
demonstrating they consider sensitivity exceptionally important.
If statistical analyses must account for discrepant weightings for
sensitivity and sensitivity, a particularly interesting question is
whose weightings should be used? Some will argue that healthcare
professionals are the best option, notably medically qualified
clinicians because they request tests, have the deepest understand-
ing of pros and cons, and thus have the broadest and most
informed perspective overall. Others will argue that society
ultimately undergoes and pays for diagnostic testing, and so
patients’ perspectives are most appropriate. This issue warrants
further research.
Our study has limitations. As noted previously, DCEs are
challenging for participants [44], requiring motivation, literacy,
and numeracy, which may introduce selection bias [23]. We
attempted to reduce this effect by using an interviewer rather than
a postal questionnaire. Although we had power for our primary
endpoint, larger and/or different samples will better investigate
differences between subcategories of patients and healthcare
professionals. Because we believed that we should not ignore
particularly strongly held beliefs, we included non-traders via
calculating median values; our estimates are therefore an
underestimate. WTP estimates are also likely underestimates
because of reluctance to state income. We followed guidelines for
best practice of DCE studies [18] but suggest that strategies for
design and analysis need further investigation [45,46]. Common to
all hypothetical scenarios, subjects’ actions in real life may not
mirror those expressed in a DCE. Finally, the weightings we
derived are specific to colorectal cancer screening. However, we
believe they are likely to be similar to other scenarios that involve
diagnosis of cancer [12].
In summary, via discrete choice experiment we found that both
patients and healthcare professionals believe gains in diagnostic
sensitivity are worth more than the perceived negative conse-
quences of a corresponding loss of specificity, when considering
colorectal cancer screening. Gains in sensitivity over loss of
specificity were valued more highly for cancer detection (vs polyps)
and by patients rather than healthcare professionals. These effects
should influence the evaluation of new screening tests.
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